Monte Rosa Therapeutics, Inc. 8-K

What Happened
Monte Rosa Therapeutics (GLUE) filed a Form 8-K on Feb. 10, 2026 announcing that Edmund Dunn will retire as SVP, Corporate Controller and Principal Accounting Officer effective April 3, 2026. The company said his departure is not due to any disagreement with the company and he will not receive severance. Matthew Bowen, age 37 and currently Director, Finance at Monte Rosa, will be promoted to Corporate Controller and Principal Accounting Officer effective April 3, 2026. Bowen joined Monte Rosa’s finance department after the company’s IPO in June 2021 and previously spent seven years in audit and assurance at Ernst & Young LLP. He holds a B.S. and M.S. in Accounting from Bryant University and is a licensed CPA in Massachusetts.

Key Details

• Effective date of change: April 3, 2026.
• Outgoing officer: Edmund Dunn — retirement not due to any disagreement; no severance or benefits on departure.
• Incoming officer: Matthew Bowen, age 37 — internal promotion from Director, Finance; ~5 years at Monte Rosa post-IPO and 7 years at Ernst & Young.
• No related-party transactions, family relationships, or special arrangements disclosed in connection with Bowen’s promotion.

Why It Matters
This is an orderly, internal succession of the company’s principal accounting officer, which supports continuity in financial reporting and compliance. For investors, the filing signals no disagreement with management, no severance cost, and that the company promoted an experienced, in-house finance executive (a CPA with Big Four audit experience) to oversee accounting functions. The notice is a standard Item 5.02 disclosure of officer departure and appointment.